title: Prognostic significance of X-ray cross-complementing gene 1 expression in gastric cancer.
abstract: OBJECTIVE
  The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 (XRCC1) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy.
  
  
  METHODS
  Immunohistochemistry (IHC) was used to evaluate XRCC1 protein expression profiles on surgical specimens of 612 gastric cancer patients. The relationship between XRCC1 expression and existing prognostic factors, platinum-based adjuvant chemotherapy, disease-free survival (DFS) and overall survival (OS) were analyzed.
  
  
  RESULTS
  Among 612 patients staged Ⅱ/Ⅲ in our study, 182 (29.74%) were evaluated as XRCC1 IHC positive. XRCC1 expression was not significantly related to OS (P = 0.347) or DFS (P = 0.297). Compared with surgery only, platinum-based adjuvant chemotherapy significantly improved the OS (P = 0.031). And the patients with negative XRCC1 expression benefited more from platinum-based adjuvant chemotherapy (P = 0.049). Multivariate analysis demonstrated that tumor size, T category, N category, vascular or nerve invasion and platinum-based chemotherapy were good prognostic factors for OS (P < 0.05). Though XRCC1 plays an important role in DNA repair pathways, no significant relationship is found in XRCC1 expression and OS among gastric cancer in our study.
  
  
  CONCLUSIONS
  XRCC1 might be an alternative prognostic marker for the patients of gastric cancer after radical resection. The patients with negative XRCC1 expression can benefit more from platinum-based adjuvant chemotherapy.
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention & Treatment, Cancer Center, Nanjing Medical University, Nanjing 210029, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention & Treatment, Cancer Center, Nanjing Medical University, Nanjing 210029, China.
authors.forename: Tongshan
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Xu
authors.affiliation: Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors.forename: WenJiao
authors.initials: W
authors.lastname: Chen
authors.affiliation: Department of Medical Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Shi
authors.affiliation: Carolinas Medical Center, University of North Carolina Charlotte Campus, Charlotte, NC 28203, USA.
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Cheng
authors.affiliation: Carolinas Medical Center, University of North Carolina Charlotte Campus, Charlotte, NC 28203, USA.
authors.forename: Ping
authors.initials: P
authors.lastname: Liu
authors.affiliation: Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
authors.forename: Xiqiao
authors.initials: X
authors.lastname: Zhou
keywords: Gastric cancer; X-ray cross-complementing gene 1 (XRCC1); platinum drugs prognosis